Member Info for Laura2022

Capitalise on growth in the cyber security market.

The worldwide cyber security market is set to be worth $345 billion by 2026 and is growing at circa 10% per year. With company losses from cybercrime set to reach $10 trillion by 2025, it is clear this rapid growth will continue.

 

Global talent shortages and widespread lack of business resources means organisations need our managed services more than ever. Increasing attacks and threats result in a growing need for cyber security solutions and our plan is to occupy a huge portion of the cyber security market. Falanx Cyber Security are in a great position to do so through:

Hi Jadam

Even 3.5p is only valuing PYC at £4mln which is woefully undervaluing its client base,contract momentum and mgmt

Razza

Had been watchign FCS for last 6mths and felt today was the right time to buy initial purchase, will add more tomorrow

I think the same

This was from Kidlington about 4 weeks ago, do it seems that several people (including Gary and also previous 3% holder Z Ali who we assume isn't there anymore because the new shares have meant he's now slightly under 3% now )have seen something in PYC that's worth being connected with

The article can also be viewed here https://jpet.aspetjournals.org/content/early/2023/06/22/jpet.122.001572

On this link you can see where all the other contributors are academically based/work for. Shows that employees/consultants of PYC are in contact scientifically ( at least) with some big companies ( AZ & GSK) on papers.

David Hodson, Hitesh, Leo and Kayode are Uni Manchester.

James Yates is GSK.

Paul Farrington, Anna Staniszewska, Sofia Guzzetti, Michael Davies are all AstraZeneca 

4 29pm

We have lots of links to USA

1) many clients there including Merck

2) new COO

3) personalised dosing tool already been trailed via DoseMeRX and also with other clinicians 3 mths ago

4) we present at the AACR annually (see April RNS) where 100s of the biggest companies are represented (new ,existing and prospective clients)

PYC have their dosing tool, which has been used within Doseme for a few years now ( thou there is some conjecture on this ) It has long been mooted that they want to expand it & be more commercial, especially within the USA pharma field. To do this, their "tool" will need Regulatory approval, especially with the FDA, and PSC help with that. Also FDA have a new thing called "project optimus" & PYC are one of the 1st UK coys attempting to trail blaze this initiative.

PSC say they can help with software and many other things that can get a product off the ground.

There could also be the thorny issue that if this is the Gary Marshall that works for PSC, and has got wind of what PYC are planning to do, and could even be the project leader ( his role )

Up 300% and 120%

FCS next

See the posts from Kidlington re; Gary

I would rather it come when we're 10p+

Clear candidate for a bio tech approach

That would send it massively

Buying here and òvb

Amati huge seller out 3mths ago

Tr1 buyers in

5mln shares issue and only £1.3 cap with £1.9mlnncash and net assets £3mln

Cyber security growth

Uxm

Maybe you should have bought here 3 weeks ago , no thanks to val

Good omen

The last one has done this on gone 3p to12p in 4 weeks (POS)

This is q hot topic

I've been adding more GRC last week and FCS today

Thabkyou

On Hl I can use a limit order , so i have placed one for £2000

Yes I am and also picked another cyber stock today (FCS)

Post there to avoid distracting from PYC

97mln has been the case for 4yrs

Now 130mln after the June placing

So not much different